Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $56.36

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen research firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $56.36.

Several research analysts have recently issued reports on KYMR shares. HC Wainwright upped their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. BTIG Research began coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price target for the company. Finally, BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a "market perform" rating and a $55.00 price objective on the stock.

Remove Ads

Kymera Therapeutics Price Performance

Shares of KYMR traded up $0.12 during midday trading on Friday, reaching $34.49. The stock had a trading volume of 374,343 shares, compared to its average volume of 519,803. The company's fifty day simple moving average is $37.43 and its two-hundred day simple moving average is $42.76. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -14.74 and a beta of 2.22. Kymera Therapeutics has a 1-year low of $29.07 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, sell-side analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,788 shares of company stock valued at $455,202. Insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after buying an additional 406 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company's stock valued at $1,649,000 after buying an additional 684 shares during the period. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after acquiring an additional 752 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company's stock valued at $534,000 after purchasing an additional 915 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.